To truly discover Rising Stars in a rapidly changing landscape that may no longer recognise traditional metrics – publication numbers, qualifications, involvement in trials, etc – with the
Among the infinite symposia, webinars, and white papers on this topic, “KOL identification” and “KOL mapping” can find themselves melting together in a gelatinous jargon
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
